share_log

Brookline Capital Reiterates Buy on Adial Pharmaceuticals, Maintains $6 Price Target

Brookline Capital Reiterates Buy on Adial Pharmaceuticals, Maintains $6 Price Target

Brookline Capital重申買入Adial Pharmicals,維持6美元的目標股價
Benzinga ·  2023/07/12 05:59

Brookline Capital analyst Kumaraguru Raja reiterates Adial Pharmaceuticals (NASDAQ:ADIL) with a Buy and maintains $6 price target.

Brookline Capital分析師Kumaraguru Raja重申了Adial Pharmicals(納斯達克股票代碼:ADIL)的買入,並維持6美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論